Prodrugs and drugs for selective ADEPT or ADC tumor therapy
Antibody tumor therapies have provided therapeutic benefit to patients with cancer, autoimmune diseases and other serious medical conditions. However, many antibodies lack sufficient intrinsic anti-tumor activity to be used as therapeutics. Scientists at the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-molar range) as well as selective antibody tumor therapeutical approaches through their prodrugs.
While a prodrug needs to have low cytotoxicity, the activated drug must on the other hand show a very high cytotoxicity in the pico-molar range. Thus, there is a high medical unmet need to have prodrugs/drugs with a big therapeutic window and extremely high and selective cytotoxicity.
Scientists at the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-molar range) as well as a selective tumor therapy through their prodrugs.
CBI moiety of Duocarmycin. Our prodrug technology is based on Duocarmycin analoga.
Preclinical:- in vitro PoC for second generation Prodrugs/Drugs.- in vivo PoC for ADEPT concept in mouse tumor models for first generation Prodrugs/Drugs.
German patent application for first generation of bifunctional prodrugs.
Dr. Stefan Uhle